We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 08, 2024
Singapore
December 18, 2024
12:00 PM - 01:30 PM ET
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Nataliya Uboha, MD, PhD
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Insights from global key opinion leaders on optimizing patient care in NSCLC
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Sagar Lonial, MD, FACP
Meghan Berkenstock, MD
Saad Z. Usmani, MD, MBA, FACP
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Joyce O'Shaughnessy, MD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education